Lantheus (NASDAQ:LNTH) Trading 4.5% Higher

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) was up 4.5% on Thursday . The company traded as high as $64.22 and last traded at $64.22. Approximately 151,982 shares were traded during trading, a decline of 85% from the average daily volume of 1,046,329 shares. The stock had previously closed at $61.48.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on LNTH shares. B. Riley lifted their target price on Lantheus from $95.00 to $99.00 and gave the company a "buy" rating in a research report on Thursday. Truist Financial reissued a "buy" rating and issued a $82.00 price target (up from $80.00) on shares of Lantheus in a research report on Monday, February 26th. StockNews.com raised Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. Finally, JMP Securities reissued a "market outperform" rating and issued a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $104.71.

Lantheus Stock Up 1.4 %

The business has a 50 day moving average price of $60.52 and a 200 day moving average price of $63.00. The stock has a market cap of $4.27 billion, a PE ratio of 13.62 and a beta of 0.53. The company has a quick ratio of 5.45, a current ratio of 5.80 and a debt-to-equity ratio of 0.69.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping the consensus estimate of $1.33 by $0.26. The business had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. Equities research analysts expect that Lantheus Holdings, Inc. will post 5.72 EPS for the current fiscal year.

Insider Transactions at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the business's stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the firm's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 94,545 shares of company stock worth $6,169,936. Corporate insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LNTH. Tucker Asset Management LLC raised its holdings in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 282 shares during the last quarter. Principal Securities Inc. purchased a new stake in shares of Lantheus during the 4th quarter valued at $28,000. First Horizon Advisors Inc. grew its stake in shares of Lantheus by 97.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 225 shares during the period. West Tower Group LLC grew its stake in shares of Lantheus by 534.1% during the 4th quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 438 shares during the period. Finally, Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider's stock valued at $36,000 after buying an additional 160 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.